Acquired Autoimmune Hemolytic Anemia Market Forecast Reaching $2.88 Billion by 2029 at 7.4% CAGR
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Are the Projected Market Size and Growth Rates for the Acquired Autoimmune Hemolytic Anemia Market From 2025 To 2029?
The market size for acquired autoimmune hemolytic anemia has been expanding remarkably in the past few years. Its growth is predicted to elevate from $2.01 billion in 2024 to $2.16 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.5%. The growth observed in the precedent period can be credited to factors such as rising diagnosis rates, increasing instances of secondary AIHA, the development of hospital hematology units, governmental and regulatory backing, and escalated investments in hematology.
In the next few years, the market size for acquired autoimmune hemolytic anemia is projected to experience significant growth, expected to reach $2.88 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this growth during the forecast period comprise an increase in the prevalence of autoimmune diseases, enhanced understanding of the complement system’s function, escalating collaboration between biopharma and academia, a rise in the application of personalized medicine, and an aging population. Emerging trends in the forecast period involve the adoption of targeted biologic therapies, progress in complement pathway inhibitors, the use of AI and data analytics in managing disease, the introduction of AI in designing clinical trials, and advancements in orphan drug development.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Acquired Autoimmune Hemolytic Anemia Market?
The growth of the acquired autoimmune hemolytic anemia market is predicted to be fueled by the rising occurrence of autoimmune disorders. Autoimmune disorders occur when the immune system erroneously attacks the body’s own healthy cells and tissues, mistaking them for harmful invaders. This increasing prevalence is largely due to the impact of environmental triggers and lifestyle alterations that may interfere with the immune system’s regulation. This surge in autoimmune disorders results in a greater incidence of acquired autoimmune hemolytic anemia since individuals with autoimmune conditions have a higher likelihood of developing secondary AIHA due to the misregulation of the immune system. For example, the autoimmune registry, a US-based organization that collects and assesses information about autoimmune disorders, reported in 2022 that the percentage of patients diagnosed with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. Hence, as autoimmune disorders become more prevalent, they are likely to influence the acquired autoimmune hemolytic anemia market’s growth.
Which Key Market Segments Comprise the Acquired Autoimmune Hemolytic Anemia Market and Drive Its Revenue Growth?
The acquired autoimmune hemolytic anemia market covered in this report is segmented –
1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Specialty Clinics, Research Institutions
Subsegment:
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
Which Areas Are Leading Regions in the Acquired Autoimmune Hemolytic Anemia Market Expansion Across the Globe?
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Acquired Autoimmune Hemolytic Anemia Market Over the Coming Years?
Major businesses that dominate the acquired autoimmune hemolytic anemia market are focusing on enhancing targeted treatments like humanized monoclonal antibodies. The goal is to increase the efficacy of therapies, minimize side effects, and offer more customized treatment alternatives for those dealing with autoimmune hemolytic anemia. A humanized monoclonal antibody is a lab-created protein made to replicate human antibodies and include small sections of non-human (usually mouse) antibodies to boost its targeted antigen interaction and lower immune system rejection. As an example, in February 2022, Sanofi, healthcare firm from France, gained approval from the U.S. Food and Drug Administration (FDA) for Enjaymo (sutimlimab-jome), making it the first exclusive treatment for cold agglutinin disease (CAD), a rare type of autoimmune hemolytic anemia. It inhibits C1s in the classical complement pathway, reducing the immune system’s premature destruction of healthy red blood cells thus lessening the necessity of red blood cell transfusions in CAD patients. Enjaymo has a specific selectivity for C1-activated hemolysis without interfering with the lectin or alternative complement pathways.
View the full report here:
How Is the Acquired Autoimmune Hemolytic Anemia Market Conceptually Defined?
Acquired autoimmune hemolytic anemia (AIHA) is a rare disorder that causes anemia when the body’s immune system unintentionally targets and kills its own red blood cells it is frequently brought on by infections, autoimmune disorders, malignancies, or specific drugs, and it can appear suddenly or gradually. This happens as a result of the body producing antibodies that attack its own red blood cells, causing hemolysis, or the premature breakdown of those cells.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
